newsfilter
← Latest News
GlobeNewswire·

Nabriva Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update

-Total revenue of $9.3 million driven by continued SIVEXTRO prescription growth- -Net product sales increased 8% sequentially in Q4 2021 versus Q3 2021- -Cash runway extended well into Q4 2022- -Conference call today at 4:30 p.m. Eastern Time-